2020-07-30
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)
Publication
Publication
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
| Additional Metadata | |
|---|---|
| doi.org/10.1038/s41375-020-0994-7, hdl.handle.net/1765/129300 | |
| Leukemia | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Ossenkoppele, G.J. (G. J.), Breems, D.A. (D. A.), Stuessi, G. (G.), van Norden, Y., Bargetzi, M., Biemond, B., A von dem Borne, P. (P.), Chalandon, Y. (Y.), Cloos, J., Deeren, D. (D.), Fehr, M. (M.), Gjertsen, B. (B.), Graux, C., Huls, G., Janssen, J.J.J.W. (J. J.J.W.), Jaspers, A. (A.), Jongen-Lavrencic, M., de Jongh, E. (E.), Klein, S.K. (S. K.), … Kuball, J. (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0). Leukemia.https://doi.org/10.1038/s41375-020-0994-7 |
|